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Abstract
The role of neutrophil elastase (NE) is poorly understood in bronchiectasis because of the lack of preclinical data
and so most of the assumptions made about NE inhibitor potential benefit is based on data from CF. In this
context, NE seems to be a predictor of long-term clinical outcomes and a possible target of treatment. In order to
better evaluate the role of NE in bronchiectasis, a systematic search of scientific evidence was performed.
Two investigators independently performed the search on PubMed and included studies published up to May 15,
2017 according to predefined criteria. A final pool of 31 studies was included in the systematic review, with a total
of 2679 patients. For each paper data of interest were extracted and reported in table.
In this review sputum NE has proved useful as an inflammatory marker both in stable state bronchiectasis and
during exacerbations and local or systemic antibiotic treatment. NE has also been associated with risk of
exacerbation, time to next exacerbation and all-cause mortality. This study reviews also the role of NE as a specific
target of treatment in bronchiectasis. Inhibition of NE is at a very early stage and future interventional studies
should evaluate safety and efficacy for new molecules and formulations.
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Background
Neutrophil elastase
Neutrophils play a key role in the pathogenesis of
numerous diseases, ranging from chronic inflammatory
disorders to infectious diseases and neoplasms [1]. Their
role in the innate immune system mainly consists in
extracellular phagocytosis, involving reactive oxygen spe-
cies, cationic proteins, and enzymes. Several granules are
sequentially formed in neutrophil cytoplasm, differing in
their propensity for exocytosis, according to their bio-
synthesis timing. Granules formed at a later stage of dif-
ferentiation shows a higher secretory potential than
those formed in immature myeloid cells, such as the
azurophilic granules containing myeloperoxidase, defen-
sins, and proteinases. Neutrophils live shortly in the
blood of healthy individuals (around 8 h), but following
inflammatory conditions they become activated and
their longevity may increase up to 5 days. The prolonged
life of neutrophils leads to functional changes and con-
tributes to the inflammatory-associated morbidity shown
in bronchiectasis patients [2].
Once inflammatory trigger develops in peripheral
tissues, neutrophils are rapidly recruited toward to the
anatomical site of inflammation. Their migration out of
the blood stream involves endothelial attachment and
rolling along the endothelium, activation, adhesion, and,
finally, trans-endothelial extravasation into the intersti-
tium. The neutrophilic inflammatory response depends
on the degranulation of pre-formed mediators from
cytoplasmatic granules and on the ability to generate
respiratory burst activity via reactive oxygen species
system. Although they ontogenetically play key functions
in antimicrobial defense, their activation can also
damage host cells and tissues. Neutrophil degranulation
is responsible for the release of several inflammatory
mediators, such as neutrophil elastase, cathepsin G, and
proteinase 3 [3].
Human neutrophil elastase (NE) is a proteolytic
enzyme belonging to the chymotrypsin-like family of the
serine-proteinases. NE is a 218 aminoacid long protein
packaged in cytoplasmatic azurophilic granules in neu-
trophil granulocytes [4]. Though NE is mainly involved
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in the response against bacteria, it can cause several
detrimental effects, including extracellular matrix
destruction, mucus gland hyperplasia and increased
mucus production, reduction of ciliary beating rate, and
direct damage to the airway epithelium [5–7]. The acid
milieu within granules protects the cell from proteolytic
activity. Upon neutrophil activation, degranulation is
triggered by the mild alkalosis resulting from the fusion
between the granules and cytoplasmic phagosomes con-
taining engulfed bacteria [8]. In addition to this intracel-
lular pathway, NE is also liberated into the extracellular
space, both free and membrane-bound. High concentra-
tions of soluble NE participate in bacterial killing at the
site of degranulation and in a small area around the cell.
More distantly, activated enzymes are completely neu-
tralized by proteinase inhibitors. On the other hand,
membrane-bound NE is remarkably resistant to inhib-
ition by the anti-proteinase system, thus preserving its
proteolytic activity. Overexpression of this mechanism
has the potential to cause tissue damage [9].
During neutrophil activation, NE-containing granules
also translocate from the cytoplasm to the nucleus,
where it is involved in the degradation of chromatin by
splitting histones. Then, neutrophils disintegrate and
release neutrophil extracellular traps (NETs). Although
this remains a controversial or fully unexplored area, this
process is hypothesized to facilitate the neutralization of
pathogens, including bacteria, fungi, and protozoa. NETs
are networks of extracellular fibers, composed of DNA
bound to histone proteins and neutrophil proteinases. NE
is the most common non-histone protein in NETs [10].
A complex interaction among proteases and anti-
proteases is required for an effective respiratory immune
system. Lower airways in patients with neutrophil
elastase-mediated lung diseases are characterized by an
excess of proteases leading to tissue destruction and
lung function decline. A1AT is the most abundant anti-
protease within the lung and the major inhibitor of NE.
A1AT is encoded by the SERPINA1 gene located on the
long arm of chromosome 14 and produced mainly by
hepatocytes and, to a lesser extent, by alveolar macro-
phages. Imbalance between NE and A1AT may be due
to either an A1AT deficiency, as documented in COPD
and emphysema, or unopposed NE activity, as proved in
CF and bronchiectasis [11]. In the latter context, NE
shows the ability to combine with polyanions (such as
DNA or glycosaminoglycans) and syndecan-1 becoming
inaccessible and limiting its inactivation by A1AT [12].
Besides NE, the serine protease group also includes
cathepsin G (Cat G) and proteinase 3 (PR3), which are
also stored in high concentrations in the azurophil
granules within the neutrophil cytoplasm [4]. Cat G is a
235-amino acid protein released during the neutrophil
activation process. Intracellularly, Cat G is released
within the phagosome to degrade engulfed pathogens;
extracellularly, it contributes to the degradation of
structural ECM components and other immune
mediators [13]. PR3 is a 222-amino acid long serine
protease encoded by the PRTN3 gene and expressed by
activated neutrophils. Its biological function is similar to
that of NE. In particular, PR3 is responsible for
proteolytic degradation and activation of IL-8 in a
truncated peptide with fostered chemoattractant effect
towards neutrophils.
NE determination assays
Different techniques have been used for NE determin-
ation. Both ready to use commercial kits and in-home
assays are useful for in vitro quantitative determination
of NE. The three most used techniques are ELISA [14],
fluorimetric [15] and spectrophotometric [16] methods.
In Table 1 some example of NE determination assays is
provided showing different samples, types of measure-
ment and detection ranges.
NE can be detected by two different methods: the
assessment of NE ability to proteolytically cleave a syn-
thetic substrate (qualitative measurement); and the
quantification of human NE concentrations in different
biological media (quantitative measurement). Both the
detection of the active enzyme and the measurement of
the amount of enzyme bound to its inhibitor, alpha-1
antitrypsin (A1AT), are techniques currently used to
measure NE in biological samples.
When ELISA assays are employed, the wells in a
microtiter plate are coated with a specific antibody able
to bind NE. ProteaseTag® is a quantitative method to
dose NE activity using NE-Tag and the subsequent anti-
body step provides additional signal amplification with
increased sensitivity with good results in a recent study
conducted by Chalmers [17].
Fluorimetric and spectrophotometric assays are based
on the ability of NE to proteolytically cleave a synthetic
substrate causing the release of a fluorophore or a
change in optical density, respectively, which can be
quantified by fluorescence or absorbance microplate
readers. Standard curves are obtained for both methods
and concentration of samples can be determined from
curve interpretation.
Commercial kits may also be used to quantify NE in
plasma, serum, cell-culture supernatant, bronchoalveolar
lavage (BAL), sputum, or whole blood. Among other
methodologies, elastin agarose diffusion plate for meas-
urement of elastolytic activity has been also reported in
previous literature [18].
Elastin degradation as a consequence of NE activity
results in the presence of elastin-derived peptides,
including desmosine and isodesmosine in serum, plasma
and urine. Both separation based on high performance
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liquid chromatography/mass spectrometry and radio-
immunoassay are validated techniques for the detection
of iso- and desmosine in body fluids [19, 20]. Finally,
high-performance capillary electrophoresis has been
applied to the study of proteases [21].
Neutrophil elastase in chronic respiratory diseases
Cystic fibrosis
An outburst of neutrophilic inflammation characterizes
CF patients and it is associated with high concentrations
of neutrophil proteases, including NE. NE has several
implications in inflammation in CF, although a compre-
hensive summary of NE effects is not in the purpose if
this review NE has an important role in the pathogenesis
of lung inflammation in CF even in the absence of any
infections. High levels of both NE and IL-8 have been
demonstrated in BAL of infants with CF [22]. A recent
study by Sly showed a correlation between NE activity in
BAL from CF children and the early development of
bronchiectasis [23].
NE is a potent upregulator of several inflammatory
chemokines, such as IL-8 and MMP-9, leading to a self-
perpetuating cycle of neutrophilic inflammation with
several detrimental effects [24]. Firstly, NE impairs cil-
iary beating and promotes expression of respiratory tract
mucins (MUC5AC and MUC5B), resulting in muco-
ciliary clearance failure [7, 25]. Secondly, NE-dependent
structural damage against elastin and other pulmonary
components leads to the irreversible airway dilation and
early bronchiectasis development. Thirdly, NE can
degradate lactoferrin, an important anti-microbial glyco-
protein as well as several molecules involved in patho-
gens’ opsonization [26–29]. Furthermore, NE can cause
impairment of lymphocytic function by degradation of
T-cell surface receptors and interfere with the process of
antigen presentation by dendritic cells [30, 31]. The sum
of all these mechanisms leads to the paradox of an over-
stimulated immune system unable to effectively kill col-
onizing pathogens.
Finally, NE may directly affect the ion transport in CF
cells acting as a potent activator of silent ENaC channels
causing increased Na absorption and further airway sur-
face dehydration and muco-ciliary dysfunction [32]. In a
recent study, Le Gars and coworkers illustrated that high
NE levels lead to CFTR loss of function via activation of
intracellular calpains that are directly responsible for the
proteolytic degradation of CFTR [33].
Treatments targeted against NE have been evaluated
in CF patients. AZD9668, a reversible oral inhibitor of
NE, when administered 60 mg twice daily orally for
4 weeks, showed no effect on sputum neutrophil counts,
NE activity, lung function or clinical outcomes, but a
consistent pattern of reduction in sputum inflammatory
biomarkers and a significant decrease of free and total
urine desmosine were reported in a double-blind ran-
domized controlled trial (RCT) enrolling ~60 CF
patients [34]. A phase-II clinical trial assessed the effi-
cacy of inhaled A1AT, with significant reduction of NE
activity and inflammatory biomarker expression without
any effects on lung function [35]. The limited efficacy
observed with both AZD9668 and A1AT in CF patients
could be mainly ascribed to the fact that the studies
were most likely too short and not powered to investi-
gate disease-modifying effects.
Chronic obstructive pulmonary disease
In patients with COPD neutrophils in sputum correlate
with severity of disease in terms of FEV1 decline and
peripheral airway dysfunction identified by high-
resolution computed tomography [36]. Several studies
highlighted that cigarette smoke and lung pollutants
activate macrophages and epithelial cells triggering the
Table 1 Neutrophil elastase determination assays
Name Samples Type of measurement Assay Unit of
measure
N° of
test
Detection range Limit of
detection
Human Elastase ELISA
(Hycult Biotech)
Plasma, Cell culture
supernatant
Active NE ELISA ng/mL 2 × 96 0.4–25 ng/mL 0.4 ng/mL
ProteaseTag® Active NE
Immunoassay (ProAxsis Ltd)
BAL, Sputum sol,
Serum free media
Active NE ELISA ng/mL 96 15.625–1000 ng/mL 7.2 ng/mL
Human PMN Elastase
ELISA Kit (Abcam)
Cell culture supernatant,
Serum, Plasma
PMN Elastase/alpha1-PI
complex
ELISA ng/mL 96 0.16–10 ng/ml 1.98 pg/mL
Neutrophil elastase
Human ELISA Kit, CE
(eBioscience)
Cell culture supernatant,
Serum, Plasma
PMN Elastase/alpha1-PI
complex
ELISA ng/mL 96 0.16–10.0 ng/mL 1.98 pg/mL
Neutrophil Elastase Activity
Assay Kit (Abcam)
Plasma, Whole Blood,
Purified protein
Active NE Fluorometric ng 100 1–25 ng 1 ng
Dynatech MR 5000
(Dynatech Corporation)
Sputum sol Active NE Spectrophotometry mcgM 96 – –
Neutrophil Elastase Activity
Assay Kit (Cayman Chemical)
Blood Active NE Fluorometric mU/mL 2 × 96 0–10 mU/mL 0.156 mU/mL
Definitions: NE neutrophil elastase, alpha1-PI alpha-1 proteinase inhibitor; PMN polymorphonuclear leukocytes
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release of neutrophil chemotactic factors [37, 38]. In this
context NE is a major determinant of tissue damage. A
landmark study on COPD-related lung tissue by
Damiano showed a positive correlation between the dis-
tribution of NE within alveolar spaces and the presence
of emphysema [39]. Instillation of human NE has been
shown to induce emphysema in the animal model, while
Shapiro and coworkers demonstrated that mice deficient
for NE expression were protected from the development
of emphysematous changes [40, 41]. More recently,
Paone have found that elevated levels of NE in COPD in
both sputum and BAL highly correlated with severity of
disease and lung function decline [42].
Treatment strategies targeting NE have been proposed
also for patients with COPD. AZD9668 was shown to
slow lung function decline and dampen the inflamma-
tory burden [43]. However, two RCTs which recruited
symptomatic COPD patients exposed to AZD9668 for
12 weeks failed to show any clinical efficacy nor benefi-
cial effects on inflammatory biomarker expression [44,
45]. This lack of efficacy may be due to inappropriate
study design in term of patients selection, relevant dose,
duration of treatment and endpoints assessments. It has
been recently demonstrated that in a subpopulation with
alpha1-antitrypsin (A1AT) deficiency, intravenous
administration of A1AT slowed the loss of lung
parenchyma [46].
Asthma
Chronic inflammation in asthma is highly heteroge-
neous. Although in the past asthma was thought as a
mere Th2-mediated inflammatory response to inhaled
antigens, neutrophils and their products have recently
been considered to play a role during both stable condi-
tions and exacerbations [47, 48]. Simpson and colleagues
showed that neutrophilic asthma is characterized by
higher concentrations of active NE, generating the
hypothesis that anti-proteases may be beneficial in the
treatment of asthmatic patients [49]. At the current
state, no studies on NE inhibitors in patients with
asthma are currently available.
Neutrophil Elastase in Bronchiectasis
Bronchiectasis is defined as an abnormal and permanent
dilation of the bronchi associated with daily cough, spu-
tum production, and recurrent respiratory infections [50].
The prevalence of bronchiectasis has risen during the last
decade both in hospital and community settings owing to
population aging, as well as widespread use of chest CT
scan and more awareness of the disease [50, 51]. The
pathophysiology of bronchiectasis is not completely
understood, particularly in view of the heterogeneity of
the disease and the absence of an animal model [52]. A
fundamental role is played by both impaired mucus
clearance and chronic bacterial infections leading to a
serious neutrophilic activation by the release of chemotac-
tic mediators. A recent study by Dente and coworkers
demonstrated that sputum neutrophils in bronchiectasis
patients correlated with worse pulmonary function,
bacterial colonization, and severe disease [53]. In this
context, NE is a key determinant of tissue damage and a
potential marker of both disease severity and activity, a
predictor of long-term clinical outcomes, and a treatment
target. In order to better evaluate the role of NE in
bronchiectasis, a systematic search of scientific evidence
on NE in bronchiectasis was performed.
Methods
Search methodology
Two investigators (AG and FA) independently performed
the search on PubMed and assessed the studies according
to predefined criteria. Reference lists of the selected
manuscripts were also manually assessed. English
language restriction was applied. This systematic revision
was conducted according to PRISMA statement [54].
Study selection
We included studies published up to May 15, 2017. Key
terms included: ‘bronchiectasis AND neutrophilic
elastase OR neutrophil elastase’; ‘bronchiectasis AND
protease’; ‘bronchiectasis AND neutrophil elastase inhib-
itors’; ‘bronchiectasis AND desmosine’. After literature
search, titles and abstracts were reviewed by two
independent investigators (AG and FA) and in case of
disagreement a final decision was taken by the principal
investigator (SA). Articles were excluded if: (1) written
in languages other than English; (2) they were case
reports, case series, or qualitative reviews; (3) NE was
not measured; (4) missing bronchiectasis patients; (5)
inclusion of CF patients; (6) inclusion of pediatric
patients; (7) full-text was unavailable. Full-text was
finally obtained for selected papers.
Data extraction and analysis
After the full-text analysis, data of interest from each
included paper were extracted. Data of interest included:
name of the first author, year of publication, study design,
sample size, assay manufacturer, biological matrix, setting,
clinical state of patients, quantitative findings and
endpoints. Corresponding authors were contacted if data
were not present or unclear in the full-text. Given the high
degree of heterogeneity across papers taken into account,
a meta-analysis was not performed.
Results
The process and results of the search are shown in Fig. 1.
The majority of the selected studies were rejected
because either they were qualitative reviews or case
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series (n = 35) or not dealing with bronchiectasis
patients (n = 34), or evaluating CF patients (n = 29)
/children (n = 5), or their full-text was not available in
English (n = 16). A final pool of 31 studies was included
in the systematic review, with a total of 2679 patients
(Table 2). Selected papers were published from 1984 to
2016, with an elevated frequency in the period 1998–
2002 (10/31, 32.3%). The majority had a cross-sectional
design (19/31, 61.3%). Only six (19.4%) studies included
patients during an acute exacerbation. Measurement of
NE was highly heterogeneous, including both commer-
cial kits and in-home assays. Sputum was the most rep-
resented biological sample for NE detection. Blood
samples were occasionally collected for NE or desmosine
measurement [17, 21, 55]. Only one (3.2%) study
detected urine desmosine. Most of the selected studies
were aimed to assess NE as an inflammatory marker
(19/31, 61.3%), while 7 (22.6%) studies investigated NE
as a marker of response to treatment and 1 (3.2%) study
evaluated NE as a target of therapy.
Discussion
Clinical relevance of NE role in bronchiectasis has been
addressed according to a multidimensional approach: its
use as inflammatory biomarkers; potential indicator of
severity of disease; predictor of clinical outcomes or
response to treatment; target of treatment.
NE as an inflammatory marker
Patients with clinically stable bronchiectasis exhibit a
permanent neutrophilic activation in the airways and
display higher sputum levels of NE and others inflamma-
tory mediators than healthy subjects [56–58]. Because of
the presence on NE-positive neutrophils in the lamina
propria, the inflammation is assumed to be driven by
NE [59].
Fujita and Chan demonstrated in different studies that
serum levels of NE-A1AT complex in patients with
bronchiectasis were significantly higher in comparison
to those of healthy subjects suggesting that lung injury is
mainly due to NE overexpression than anti-proteinase
system deficiency [12, 60, 61].
Angrill proposed that airway inflammation is perman-
ent and may occur even in the absence of bacterial
colonization, as demonstrated by the increase of NE and
other inflammatory mediators in the BAL of 49 patients
in comparison with healthy subjects [62]. Previous
studies reported that purulent sputum was associated
with NE concentration, and can be considered a marker
for proteolytic and inflammatory activity [18, 63–65].
These findings were consistent with recent data reported
by Goeminne who demonstrated a strong correlation be-
tween sputum purulence and proteolytic enzymes, both
of which seem to predict the degree of inflammation
and disease severity in bronchiectasis [66].
Fig. 1 Flow-chart of the systematic review
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Moreover, NE has been shown to progressively increase
with increasing bacterial load in sputum. Chalmers also
reported on a strong association between sputum bacterial
load and a cluster of inflammatory mediators in a cohort of
434 bronchiectasis patients [16, 67]. Finally, high levels of
NE have been documented in special phenotypes of bron-
chiectasis patients, such as those with chronic infection
with both P. aeruginosa and other bacteria [68–70].
As a marker of airway inflammation, NE also increases
during exacerbations and decreases after a short course
of oral antibiotic treatment [6, 67, 71, 72]. These data
suggest that NE may act as marker of airway inflamma-
tion both in stable patients and during exacerbations.
A correlation between gastroesophageal reflux disease
(GERD) and higher levels of NE is also reported [73].
NE as a predictor of clinical outcomes or response to
treatment
The identification of a biomarker to assess disease severity
and predict progression and outcomes is still an unmet
need in bronchiectasis [51]. In the past decades, several
experiences showed that NE is associated with clinical
outcomes in different bronchiectasis cohorts [66, 74, 75].
Tsang and coworkers showed a correlation between spu-
tum elastase, radiological involvement, and functional
markers in a sample of 30 bronchiectasis patients [75].
However, the heterogeneity of measurement assays for NE
among different cohorts and the lack of relevant follow-up
periods may have affected the findings. Recently, NE
underwent a prospective validation in a large cohort of
patients followed over 3 years. This sample was divided
into three groups according to negative, intermediate, and
high elastase activity levels. NE activity was independently
associated with lung function decline over 3 years with a
loss of 56.4 ml per year in the high activity group
(+20.8 ml in comparison with negative-NE group). In
addition, NE was also independently associated with the
risk of future exacerbations, shorter time to next exacer-
bation, and all-cause mortality [17].
In a recent evaluation of clinical phenotypes, the pheno-
type of patients with chronic infection with P. aeruginosa
or other bacteria was associated with both higher NE con-
centrations and worse clinical outcome [70]. This finding
is consistent with a meta-analysis by Finch which showed
that P. aeruginosa chronic infection is associated with a
threefold increased risk of death and an increase in
hospital admissions and exacerbations [76].
Future clinical trials are needed to validate cut-off of
NE activity and implement NE as a useful biomarker in
the clinical management of bronchiectasis patients.
Local or systemic antibiotic therapy and consequent
reduction of bacterial load has been hypothesized to
decrease sputum NE levels. Previous findings suggest that
short oral courses of antibiotic therapy are effective in
reducing NE activity in sputum [6, 67, 71]. Chalmers and
Murray proved that long-term nebulized gentamycin
significantly reduces free elastase activity in sputum, as
well as sputum MPO levels and bacterial load [67, 77].
Roxithromycin treatment may reduce sputum NE in
bronchiectasis patients as recently demonstrated by Liu
in an open-label 6-month study. These findings demon-
strate that macrolide therapy may be beneficial in
bronchiectasis and may contribute to the understanding
of underlying mechanisms [14, 78].
Selected anti-inflammatory drugs have also been
tested as indirect modulators of neutrophilic inflamma-
tion in bronchiectasis. In a study by Llewellyn-Jones, a
4-week treatment with indomethacin appeared to have
no effect on lung inflammation, as assessed by no
significant difference in neutrophil and NE activity
within the sputum [15].
NE as a target of treatment
Since NE is a major driver of neutrophilic inflammation
in bronchiectasis, it has been proposed to tailor treat-
ment aimed to its direct or indirect inhibition, see Fig. 2.
AZD9668 is a NE inhibitor previously investigated in
chronic respiratory diseases, including COPD and CF,
with inconclusive results [34, 44, 45]. In a small phase II
double-blind trial conducted in 10 different centres, 38
patients were randomized to 4 weeks of oral AZD9668
twice daily. AZD9668 increased FEV1 (by about 100 mL)
and slowed vital capacity (by about 130 mL) compared
with the placebo group. A trend in reduction of most
inflammatory biomarkers was also reported (IL-6 and
IL-8). There were no differences between AZD9668 and
placebo arms regarding sputum quantity, symptoms, and
quality of life. The Authors suggested larger studies of
longer duration to assess beneficial effects [55, 79].
BAY 85–8501 is a selective NE inhibitor that has
shown efficacy in pre-clinical pharmacological and
animal models [80]. A phase II randomized parallel
group study assessed the safety and tolerability of 28-day
oral administration of BAY 85–8501 in 94 bronchiectasis
patients. BAY 85–8501 was generally well tolerated and
there were no significant changes in lung function, 24 h
sputum quantity, NE activity and concentration, and
other biomarkers including urine desmosine [81]. Short
duration of treatment and inadequate drug concentra-
tion at the target site may be the cause of this lack of
efficacy. Regarding this last point, it is reasonable that
the inhaled approach instead of the oral administration
could allow reaching higher lung concentrations with
limited systemic exposure and consequent side effects,
thus permitting to counteract that elevated amount of
active NE found in the patient’s airways.
With this rationale, CHF6333 is the first inhaled NE
inhibitor under development for the treatment of NE-
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driven lung diseases as dry powder inhaler. In in vitro
assays, CHF6333 is highly potent in inhibiting human
NE (IC50 = 0.2 nM) with good selectivity against other
proteases. In addition, CHF6333 significantly reduces
lung neutrophil recruitment induced by cigarette smoke
exposure in mice and reduces both lung tissue infection
and inflammation when administered intratracheally to
P. aeruginosa lung infected rats for 7 days [82].
A phase I trial to investigate safety and pharmacokin-
etics on healthy male subjects is still in phase of recruit-
ment (clinicaltrial.gov ID NCT03056326).
Conclusions
Sputum NE has proved useful as an inflammatory
marker both in stable state bronchiectasis and during
exacerbations and local or systemic antibiotic treatment.
NE has also been associated with risk of exacerbation,
time to next exacerbation and all-cause mortality.
Inhibition of NE as a specific target of treatment in
bronchiectasis is at a very early stage. Future interven-
tional studies should evaluate safety and efficacy for new
molecules and formulations.
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